[EN] AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE<br/>[FR] INHIBITEURS À BASE DE TRIAZOLOPYRAZOLE, TRIAZOLOTHIADIAZOLE DE LA PROTÉINE KINASE C-MET
申请人:VERTEX PHARMA
公开号:WO2010138665A1
公开(公告)日:2010-12-02
The present invention relates to compounds of formula (I), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula (I) and methods of using the compositions in the treatment of proliferative disorders.
[EN] INHIBITORS OF C-MET PROTEIN KINASE<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE C-MET
申请人:VERTEX PHARMA
公开号:WO2010138673A1
公开(公告)日:2010-12-02
The present invention relates to compounds of formula (I), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE
申请人:Lauffer David
公开号:US20130018072A1
公开(公告)日:2013-01-17
The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE
申请人:Lauffer David
公开号:US20110124684A1
公开(公告)日:2011-05-26
The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.